<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01995617</url>
  </required_header>
  <id_info>
    <org_study_id>GEN-004-001</org_study_id>
    <nct_id>NCT01995617</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of GEN-004, a Streptococcus Pneumoniae Protein Subunit Vaccine, in Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genocea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genocea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GEN-004 is a combination of 3 conserved proteins from Streptococcus pneumoniae. This is a&#xD;
      randomized, double-blind, placebo-controlled, dose escalation study. Eligible subjects (male&#xD;
      and non-pregnant female) will be assigned sequentially to 1 of 3 dose cohorts and randomized&#xD;
      in a 3:1:1 ratio to receive GEN-004 with adjuvant, GEN-004 without adjuvant, or placebo,&#xD;
      respectively. Each subject will receive up to 3 doses at 4 week intervals.&#xD;
&#xD;
      Subjects will be followed for safety, tolerability, and immunogenicity for 12 months after&#xD;
      their last dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of GEN-004 when administered with and without aluminum hydroxide to adult subjects.</measure>
    <time_frame>12 months after third (last) dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the immunogenicity of GEN-004, as measured by TH17 (IL-17) and IgG responses to the antigens, when administered with and without aluminum hydroxide.</measure>
    <time_frame>12 months after third (last) dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the durability of immune responses up to 12 months after the last dose.</measure>
    <time_frame>12 months after third (last) dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Streptococcus Pneumoniae</condition>
  <arm_group>
    <arm_group_label>Low Dose (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid Dose (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>normal saline, 0.5 mL per dose</description>
    <arm_group_label>High Dose (Cohort 3)</arm_group_label>
    <arm_group_label>Low Dose (Cohort 1)</arm_group_label>
    <arm_group_label>Mid Dose (Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEN-004 Low Dose</intervention_name>
    <description>The GEN-004 Low Dose contains 10µg of each of the three antigens.</description>
    <arm_group_label>Low Dose (Cohort 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEN-004 Low Dose + Adjuvant</intervention_name>
    <description>The GEN-004 Low Dose contains 10µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.</description>
    <arm_group_label>Low Dose (Cohort 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEN-004 Mid Dose</intervention_name>
    <description>The GEN-004 Mid Dose contains 30µg of each of the three antigens.</description>
    <arm_group_label>Mid Dose (Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEN-004 Mid Dose + Adjuvant</intervention_name>
    <description>The GEN-004 Mid Dose contains 30µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.</description>
    <arm_group_label>Mid Dose (Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEN-004 High Dose</intervention_name>
    <description>The GEN-004 High Dose contains 100µg of each of the three antigens.</description>
    <arm_group_label>High Dose (Cohort 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEN-004 High Dose + Adjuvant</intervention_name>
    <description>The GEN-004 High Dose contains 100µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.</description>
    <arm_group_label>High Dose (Cohort 3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and non-pregnant females, ages 18 to 55 years inclusive.&#xD;
&#xD;
          2. Willing and able to provide written informed consent.&#xD;
&#xD;
          3. Willing to perform and comply with all study procedures including attending clinic&#xD;
             visits as scheduled.&#xD;
&#xD;
          4. Willing to practice adequate contraception that may include, but is not limited to,&#xD;
             abstinence, monogamous relationship with vasectomized partner, vasectomy, barrier&#xD;
             methods such as condoms, diaphragms, intrauterine devices, and licensed hormonal&#xD;
             methods for 28 days before and 90 days after receiving Study Drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Immunocompromised individuals, including those receiving immunosuppressive doses of&#xD;
             corticosteroids (more than 20 mg of prednisone given daily or on alternative days for&#xD;
             2 weeks or more within 6 months prior to the first dose of Study Drug, any dose of&#xD;
             corticosteroids within 30 days of the first dose of Study Drug, or high dose inhaled&#xD;
             corticosteroids [&gt; 960 µg/day of beclomethasone dipropionate or equivalent]) or other&#xD;
             immunosuppressive agents.&#xD;
&#xD;
          2. Presence or history of autoimmune disease, regardless of current treatment.&#xD;
&#xD;
          3. Insulin dependent diabetes.&#xD;
&#xD;
          4. Positive serologic test for HIV-1 or hepatitis C infection; positive hepatitis B&#xD;
             surface antigen (HBsAg).&#xD;
&#xD;
          5. Screening serum chemistry or hematology abnormality ≥ Grade 1.&#xD;
&#xD;
          6. Screening urinalysis abnormality ≥ Grade 2.&#xD;
&#xD;
          7. Positive urine drug screen or alcohol Breathalyzer test at Screening or on Study Day&#xD;
             1.&#xD;
&#xD;
          8. Other active, uncontrolled co-morbidities that, in the opinion of the Investigator&#xD;
             would make the subject unsuitable for the study or unable to comply with the study&#xD;
             requirements.&#xD;
&#xD;
             NOTE: Subjects who are taking a medication to control an underlying co-morbidity may&#xD;
             be enrolled if there have been no changes to their medication within 60 days prior to&#xD;
             the first dose of Study Drug.&#xD;
&#xD;
          9. Any acute illness including, fever (&gt;100.4 degrees F [&gt; 38 degrees C]) within 3 days&#xD;
             prior to the first dose of Study Drug.&#xD;
&#xD;
         10. Pregnant or nursing women.&#xD;
&#xD;
         11. Receipt of any investigational drug within 30 days prior to the first dose of Study&#xD;
             Drug.&#xD;
&#xD;
         12. Receipt of blood products within 90 days prior to the first dose of Study Drug.&#xD;
&#xD;
         13. Donation of blood or plasma within 56 days prior to Screening.&#xD;
&#xD;
         14. Receipt of a live vaccine within 28 days prior or a subunit vaccine within 14 days&#xD;
             prior to the first dose of Study Drug or planned vaccination within 30 days following&#xD;
             the last dose of Study Drug.&#xD;
&#xD;
         15. Prior vaccination with pneumococcal vaccine.&#xD;
&#xD;
         16. History of hypersensitivity to any component of the vaccine or history of an allergic&#xD;
             reaction to an immunization.&#xD;
&#xD;
         17. History of invasive pneumococcal disease (i.e., sepsis, meningitis or pneumonia with&#xD;
             bacteremia).&#xD;
&#xD;
         18. History of drug or alcohol abuse that, in the opinion of the Investigator, would&#xD;
             interfere with the subject's ability to comply with the study requirements.&#xD;
&#xD;
         19. Any other condition that, in the opinion of the Investigator would make the subject&#xD;
             unsuitable for the study or unable to comply with the study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Matson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prism Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prism Research</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>November 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2013</study_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>Streptococcus pneumoniae</keyword>
  <keyword>Strep pneumo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

